Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

A number of other research analysts have also recently weighed in on ALNY. Citigroup initiated coverage on Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target for the company. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a report on Friday, May 1st. Royal Bank Of Canada cut their price objective on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a report on Friday, May 1st. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $461.39.

Alnylam Pharmaceuticals Trading Up 1.4%

NASDAQ:ALNY traded up $4.52 during trading hours on Tuesday, reaching $317.56. 38,850 shares of the stock were exchanged, compared to its average volume of 1,245,290. Alnylam Pharmaceuticals has a twelve month low of $273.11 and a twelve month high of $495.55. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The business has a 50-day moving average of $295.49 and a two-hundred day moving average of $327.31. The company has a market capitalization of $42.40 billion, a price-to-earnings ratio of 86.51 and a beta of 0.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.44) earnings per share. On average, equities analysts predict that Alnylam Pharmaceuticals will post 7.36 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $243,000. Geneos Wealth Management Inc. grew its holdings in Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 175 shares in the last quarter. Flow Traders U.S. LLC acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $241,000. Daiwa Securities Group Inc. raised its stake in Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its position in Alnylam Pharmaceuticals by 70,300.0% during the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock worth $229,000 after acquiring an additional 703 shares during the period. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.